AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06376526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg
Study NCT05332600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drop-jump test
Description: The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
Study NCT05193214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-PD-1 humanized monoclonal antibody injection
Description: Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
Study NCT05094622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: A specially designed exercise training program based on a previous study. The intervention of physical exercise will consist of different exercises to enhance muscle strength and endurance and will be individually adjusted and start in a different position with a progression in dose, intensity, and position. It will be performed 3 times /week during a period of 12-20 weeks.
Study NCT05497180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive myofunctional appliance
Description: passive myofunctional appliance
Study NCT05497180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard oral appliance
Description: standard oral appliance
Study NCT05098028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Rifaximin ER
Description: Low Dose Rifaximin Extended Release Twice Daily
Study NCT05098028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Rifaximin DER
Description: Low Dose Rifaximin Delayed Extended Release Twice Daily
Study NCT05098028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Rifaximin ER
Description: High Dose Rifaximin Extended Release Twice Daily
Study NCT05098028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Rifaximin DER
Description: High Dose Rifaximin Delayed Extended Release Twice Daily
Study NCT05098028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Twice Daily
Study NCT05752760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus Plantarum 299v Freeze Dried Capsule
Description: The intervention is a probiotic lactobacillus that is contained in food products in the US
Study NCT05752760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Freeze Dried Potato Starch Capsule
Description: The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
Study NCT04463771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
Study NCT06459739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral ESPB
Description: sacral ESPB
Study NCT04463771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat will be administered orally BID.
Study NCT04463771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: pemigatinib will be administered orally QD.
Study NCT04463771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN2385 will be administered every 2 weeks
Study NCT04463771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN2390 will be administered every 2 weeks
Study NCT06404099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks.
Study NCT06404099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil Placebo
Description: The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
Study NCT06404099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solriamfetol
Description: The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.
Study NCT06404099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solriamfetol Placebo
Description: The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
Study NCT06366737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KILBON Appliance
Description: palatal TAD assissted lingual appliance for en-mass retraction
Study NCT06366737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAT appliance
Description: palatal TAD assissted clear aligner
Study NCT05979064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopically harvested omental tissue autograft
Description: 1. Standard neurosurgical removal of recurrent GBM,~2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~3. the omental fat will be transferred and implanted into brain tumor cavity,~4. standard closure of surgical resection cavity.
Study NCT06212804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.
Study NCT06212804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: VIS954 Placebo
Study NCT05842031 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Description: Identify what interventions may be helpful in improving quality of life.
Study NCT05842031 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Educational Needs
Description: Identify what interventions may be helpful in improving patient educational needs
Study NCT05842031 — intervention group
Intervention type: BEHAVIORAL
Intervention: Symptom Management
Description: Identify what interventions may be helpful in improving symptom management Improve symptom management
Study NCT05952349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)
Description: 44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
Study NCT05952349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin (1000 mg Twice a day)
Description: 44 Patients with PCOS receiving Metformin 1000mg (BD)
Study NCT05957679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRE and routine MRI
Study NCT05957679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment and Recording
Description: Undergo grading and recording of tumor stiffness and adhesion during surgery
Study NCT06241742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Single, oral dose of HT-6184
Study NCT06241742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Single, oral dose of placebo
Study NCT04935957 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GLUCUBE device
Description: device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
Study NCT06444412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT06444412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06444412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga 68 PSMA-11
Description: Contrast dye given IV
Study NCT06444412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05470673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole
Description: Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
Study NCT05470673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using autogenous demineralized dentin graft alone
Description: Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
Study NCT05803031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melaleuca Alternifolia Oil
Description: Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min.
Study NCT05803031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal debridement
Description: Scaling and root surface debridement
Study NCT05803031 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal debridement
Description: Scaling and root surface debridement
Study NCT05763810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block
Study NCT05763810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
Description: Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
Study NCT03655132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Acceptance and Commitment Therapy for Chronic Pain
Description: Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
Study NCT04819464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 0.5 mg.
Study NCT05007613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG
Description: Cabozantinib (Cabometyx) 40 MG PO QD
Study NCT05007613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection
Description: atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
Study NCT05514600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of parastomal hernia fascial defect
Description: For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.
Study NCT04722900 — intervention group
Intervention type: OTHER
Intervention: intrauterine exposure to elevated glucose levels
Description: intrauterine exposure to elevated glucose levels
Study NCT05428332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-Compartment Unloader Brace
Description: Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
Study NCT06208657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib, Irinotecan, Temozolomide
Description: Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
Study NCT06208657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
Study NCT06362850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tele-support
Description: via real-time audio-video connection through an experienced physician
Study NCT06168097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis
Description: 1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis.
Study NCT06168097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: women with intraoperative and / or histopathology findings suggestive of endometriosis
Description: 1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis.
Study NCT06580496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier
Description: Mightier is a pediatric at-home intervention program that includes an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14. The program also uses physical materials including printed workbooks and conversation cards that focus on teaching additional Cognitive Behavioral Therapy (CBT)-based skills and concepts.
Study NCT05200143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
Study NCT05200143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
Study NCT05200143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
Study NCT06526260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Brief Exposure to Facial Expressions
Description: In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.
Study NCT04988295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.
Study NCT04988295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion.
Study NCT04988295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.
Study NCT04988295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an IV infusion.
Study NCT04988295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.
Study NCT04988295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered as an IV infusion.
Study NCT05950464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05950464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05950464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05950464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05950464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo ECG
Study NCT05950464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05950464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO
Study NCT05950464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT05355571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LAB4 + Saccharomyces boulardii
Description: Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
Study NCT05355571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo